CRI Worldwide

Willingboro, New Jersey 20850

0 studies enrolling now · 14 studies all time

What they study most

Bipolar I Disorder, Central Nervous System Diseases, Chronic Schizophrenia, Cognition, Hepatitis C, Inflammatory Bowel Disease, Low Back Pain, Major Depressive Disorder, Obesity, Peanut Allergy, Schizoaffective Disorder, Schizophrenia

Studies at this site

• A Study of Tanezumab in Adults With Chronic Low Back Pain — Completed
• Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD) — Stopped early
• Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State — Completed
• Crossover Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets Under Steady State Fasted Conditions — Completed
• Single Ascending Dose Study of RBP-7000 — Completed
• First in Man Study of Safety, Tolerability and PK Profile of RBP-7000 — Completed
• Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia. — Completed
• Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia — Completed
• Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia — Completed
• Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia — Completed
• Major Depressive Disorder With Mixed Features — Withdrawn before enrolling
• Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection — Completed
• Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy — Completed
• Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose — Completed